Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone

Drug and Alcohol Dependence

Volumn 105, Issue 3, 2009, Pages 234-239

  Bruce, R Douglas ^a   Altice, Frederick L ^a   Moody, David E ^b   Lin, Shen Nan ^b   Fang, Wenfang B ^b   Sabo, John P ^c   Wruck, Jan M ^c   Piliero, Peter J ^c   Conner, Carolyn ^c   Andrews, Laurie ^a   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Antiviral treatment; Buprenorphine naloxone; HIV AIDS; Maintenance; Opiates; Pharmacokinetics; Pharmacotherapy; Ritonavir; Substance abuse; Tipranavir

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; OPIATE; RITONAVIR PLUS TIPRANAVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPIATE ADDICTION; PARESTHESIA; PRIORITY JOURNAL; SERODIAGNOSIS; SIDE EFFECT; STEADY STATE;

ADULT; ANTI-RETROVIRAL AGENTS; BUPRENORPHINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PYRIDINES; PYRONES; RITONAVIR; TREATMENT OUTCOME;

PEPPER GOLDEN MOSAIC VIRUS - [MEXICO];

EID: 70349865184     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.07.007     Document Type: Article

References (38)

1. Altice F.L., Friedland G.H., and Cooney E.L. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13 (1999) 957-962
2. Altice F.L., Sullivan L.E., Smith-Rohrberg D., Basu S., Stancliff S., and Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin. Infect. Dis. 43 Suppl. 4 (2006) S178-183
3. Basu S., Smith-Rohrberg D., Bruce R.D., and Altice F.L. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin. Infect. Dis. 42 (2006) 716-721
4. Bruce R.D., and Altice F.L. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 20 (2006) 783-784
5. Bruce R.D., and Altice F.L. Clinical care of the HIV-infected drug user. Infect. Dis. Clin. North Am. 21 (2007) 149-179
6. Bruce R.D., Altice F.L., Gourevitch M.N., and Friedland G.H. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41 (2006) 563-572
7. Bruce R.D., Altice F.L., and Friedland G.H. HIV disease among substance users: treatment issues. In: Volberding P. (Ed). Global HIV/AIDS Medicine (2007), Elsevier, New York
8. Bruce R.D., McCance-Katz E., Kharasch E.D., Moody D.E., and Morse G.D. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin. Infect. Dis. 43 Suppl. 4 (2006) S216-223
9. Chang Y., Moody D.E., and McCance-Katz E.F. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos.: Biol. Fate Chem. 34 (2006) 440-448
10. Chang Y., and Moody D.E. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UGT supersomes. Drug Metab. Lett. 3 (2009) 101-107
11. Cone E.J., Gorodetzky C.W., Yousefnejad D., Buchwald W.F., and Johnson R.E. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos.: Biol. fate Chem. 12 (1984) 577-581
12. Cooper C., van Heeswijk R., Bilodeau M., Kovacs B., Sabo J., MacGregor T., Wruck J., Elgadi M., Neubacher D., and McCallister S. The pharmacokinetics (PK) of single dose and steady-state tipranavir/ritonavir (TPV/R) 500 mg/200 mg in subjects with mild or moderate hepatic impairment. Sixth International Workshop on Clinical Pharmacology of HIV Therapy. Montreal, Canada (2005)
13. Doran C.M., Shanahan M., Mattick R.P., Ali R., White J., and Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 71 (2003) 295-302
14. Elkader A., and Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 44 (2005) 661-680
15. Fang W.B., Chang Y., McCance-Katz E.F., and Moody D.E. Determination of naloxone and nornaloxone (noroxymorphone) by high performance liquid chromatography-electrospray ionization-tanden mass spectrometry. J. Anal. Toxicol. 33 (2009) 409-417
16. Fiellin D.A., and O'Connor P.G. Clinical practice. Office-based treatment of opioid-dependent patients. New Engl. J. Med. 347 (2002) 817-823
17. Friedland G., Andrews L., Schreibman T., Agarwala S., Daley L., Child M., Shi J., Wang Y., and O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19 (2005) 1635-1641
18. Handelsman L., Cochrane K.J., Aronson M.J., Ness R., Rubinstein K.J., and Kanof P.D. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 13 (1987) 293-308
19. Kerr T., Wodak A., Elliott R., Montaner J.S., and Wood E. Opioid substitution and HIV/AIDS treatment and prevention. Lancet 364 (2004) 1918-1919
20. King C.D., Green M.D., Rios G.R., Coffman B.L., Owens I.S., Bishop W.P., and Tephly T.R. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch. Biochem. Biophys. 332 (1996) 92-100
21. la Porte C.J.L., Cameron D.W., Sabo J.P., Murray G.E., Fagan N., Bosisio M., Jones P., and Di Perri G. The effect of omeprazole, food and formulation on the pharmacokinetics of tipranavir coadministered with ritonavir (TPV/r). Eight International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary (2007)
22. la Porte C.J.L., Sabo J.P., Beique L., Moy F., Zaki R., and Cameron D.W. Lack of effect of efavirenz (EFV) 600 mg qD on the pharmacokinetics of tipranavir/ritonavir 500/200 mg BID (TPV/r) in healthy volunteers. 47th ICAAC. Chicago, IL (2007)
23. Lucas G.M., Gebo K.A., Chaisson R.E., and Moore R.D. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16 (2002) 767-774
24. Lucas G.M., Mullen B.A., McCaul M.E., Weidle P.J., Hader S., and Moore R.D. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDs 21 (2007) 564-574
25. Lucas G.M., Mullen B.A., Weidle P.J., Hader S., McCaul M.E., and Moore R.D. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin. Infect. Dis. 42 (2006) 1628-1635
26. MacGregor T.R., Sabo J.P., Norris S.H., Johnson P., Galitz L., and McCallister S. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5 (2004) 371-382
27. McCallister S., Sabo J., Galitz L., and Mayers D. An open-label steady state investigation of the pharmacokinetics (PK) and tipranavir (TPV) and ritonavir (RTV) and their Effects on cytochrome P-450 (3A4) in normal healthy volunteers (BI 1182.5). 434-W. 9th Conference on Retroviruses and Opportunistic Infections (2002), Foundation for Retrovirology and Human Health
28. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., and Foltz R.L. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 306 (2002) 31-39
29. Pham P., Lee L., Fuchs E., Barditch-Crovo P., Carson K., Radebaugh C., Everts S., Piliero P., and Flexner C. Pharmacokinetic interaction between tipranavir/ritonavir and rosuvastatin. Conference on Retroviruses and Opportunistic Infections. Boston, MA (2008)
30. Ritonavir package insert. Product information: norvir (R). Ritonavir (2007), Abbott Laboratories
31. Sabo J.P., Cong X.J., Haas D., Eskoetter H., Kraft M., and Mauss S. Lack of a pharmacokinetic effect between steady-state tipranavir/ritonavir (TPV/r) and single dose valacyclovir in healthy subjects. 48th ICAAC. Washington, DC (2008)
32. Sabo J.P., Piliero P.J., Lawton A., MacGregor T.R., and Leith J. A comparison of steady-state trough plasma ritonavir concentrations for HIV+ patients receiving an optimized background regimen and ritonavir-boosted tipranavir (TPV/r), lopinar (LPV/r), saquinavir (SQV/r) or amprenavir (APV/r). 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006)
33. Spire B., Lucas G.M., and Carrieri M.P. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int. J. Drug Policy 18 (2007) 262-270
34. Tipranavir Package Insert. Product Information: Aptivus (r). Tipranavir (2005), Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
35. Valdez H., Sabo J., wruck J., MacGregor T., Garfinkel S., Chen L., Philip E., Mao Y., McCallister S., and Norris S. Tipranavir (TPV) Excretion mass balance and metabolite profile when co-administered with ritonavir (RTV). 44th ICAAC. Washington, DC (2004)
36. van Heeswijk R., Sabo J.P., MacGregor T., Elgadi M., Harris F., McCallister S., and Mayers D. The pharmacokinetic interaction between single-dose rifabutin and steady-state tipranavir/ritonavir 500 mg/200 mg (TPV/r) in healthy volunteers. 44th ICAAC. Washington, DC (2004)
37. van Heeswijk R., Sabo J.P., Norris S.H., Johnson P., Galitz L., and McCallister S. The pharmacokinetic interaction between tipranavir/ritonavir 500 mg/200 mg bid (tipranavir/r) and atorvastatin antacid and CYP3A4 in healthy volunteers. Fifth International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy (2004)
38. Vourvahis M., and Kashuba A.D. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27 6 (2007) 888-909